STAT3 and diffuse large B-cell lymphoma: OPB‐111077, another novel inhibitor of STAT3, also exhibits promising anti-cancer activity in patients with diffuse large B‐cell lymphoma (DLBCL) and modest efficacy was observed against other tumors, including GC, when given as a monotherapy (225).